Replies to post #239940 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Speaking of ICI-related toxicities, here's a batch of new reports in the last few months:-

"Encephalitis identified as rare toxicity of immunotherapy treatment"
https://www.sciencedaily.com/releases/2019/07/190722115941.htm

"Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors"
https://www.sciencedirect.com/science/article/pii/S0959804917310171

"Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System"

"Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?"
https://www.ncbi.nlm.nih.gov/pubmed/30659547

"Case report: Immune-mediated cerebellar ataxia secondary to anti-PD-L1 treatment for lung cancer"
https://www.tandfonline.com/doi/abs/10.1080/00207454.2019.1655013?journalCode=ines20

"Immune Checkpoint Inhibitor Toxicities"
https://www.mayoclinicproceedings.org/article/S0025-6196(19)30275-7/fulltext

"A new expression of immune checkpoint inhibitors’ renal toxicity: when distal tubular acidosis precedes creatinine elevation"
https://academic.oup.com/ckj/advance-article/doi/10.1093/ckj/sfz051/5489323

"Diabetes mellitus secondary to treatment with immune checkpoint inhibitors"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380640/

"Immune-Related Adverse Events Requiring Hospitalization in Patients Receiving Immune Checkpoint Inhibitors"
https://www.ascopost.com/News/60343